TECARTUS
NDC 71287-220, brexucabtagene autoleucel, suspension, from Kite Pharma, Inc..
- Product NDC
- 71287-220
- Status
- Listed
- Labeler
- Kite Pharma, Inc.
- Dosage form
- SUSPENSION
- Route
- INTRAVENOUS
- Product type
- CELLULAR THERAPY
- Marketing category
- BLA
- Application
- BLA125703
- DEA schedule
- None
curl https://api.healthcare.dev/v1/drugs/ndc/71287-220 \ -H "Authorization: Bearer $HDEV_API_KEY"
Product
Active ingredients and packages
Active ingredients
- BREXUCABTAGENE AUTOLEUCEL1000000 1/68mL
| Package NDC | NDC-11 | Package |
|---|---|---|
| 71287-220-02 | 71287022002 | 1 BAG in 1 PACKAGE (71287-220-02) / 68 mL in 1 BAG (71287-220-01) |
Linked data
RxNorm, label and prices
Related lookups
Medicare Part B payment limits (ASP)
GET /v1/drugs/asp?ndc=71287-220
Use it
Look up 71287-220 from code or an agent
curl https://api.healthcare.dev/v1/drugs/ndc/71287-220 \ -H "Authorization: Bearer $HDEV_API_KEY"
Using the healthcare.dev MCP server, look up NDC 71287-220. Tell me the product, its labeler, dosage form and route, its packages, and the RxNorm concepts it maps to.
Source: FDA, release 2026-10-23. Public domain. Reference data, not medical advice.